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We investigated the use of purinergic receptors as a new
treatment modality for nonmelanoma skin cancers.
Purinergic receptors, which bind adenosine 50 -tri-
phosphate, are expressed on human cutaneous keratino-
cytes. Previous work in rat and human epidermis sug-
gested functional roles for purinergic receptors in the
regulation of proliferation, di¡erentiation, and apopto-
sis. Immunohistochemical analysis of frozen sections in
human basal cell carcinomas and squamous cell carci-
nomas for P2X5, P2X7, P2Y1, P2Y2, and P2Y4 receptors
was performed, accompanied by detailed analysis of ar-
chive material of tumor subtypes in para⁄n sections.
Functional studies were performed using a human cuta-
neous squamous cell carcinoma cell line (A431), where
purinergic receptor subtype agonists were applied to
cells and changes in cell number were quanti¢ed via a
colorimetric assay. Immunostaining in para⁄n sections
was essentially the same as that in frozen sections,
although more detail of the subcellular composition
was visible. P2X5 and P2Y2 receptors were heavily ex-
pressed in basal cell carcinomas and squamous cell car-
cinomas. P2X7 receptors were expressed in the necrotic
center of nodular basal cell carcinomas and in apoptotic
cells in super¢cial multifocal and in¢ltrative basal cell
carcinomas, and squamous cell carcinomas. P2Y1 re-
ceptors were only expressed in the stroma surrounding
tumors. P2Y4 receptors were found in basal cell carci-
nomas but not in squamous cell carcinomas. P2X5 re-
ceptors appear to be associated with di¡erentiation.
The P2X7 receptor agonist benzoylbenzoyl-adenosine
50 -triphosphate and high concentrations of adenosine
50 -triphosphate (1000^5000 lM) caused a signi¢cant re-
duction in A431 cell number (po0.001), whereas the
P2Y2 receptor agonist uridine 50 -triphosphate caused a
signi¢cant amount of proliferation (po0.001). We have
demonstrated that non-melanoma skin cancers express
functional purinergic receptors and that P2X7 receptor
agonists signi¢cantly reduce cell numbers in vitro. Key
words: adenosine triphosphate/apoptosis/basal cell/carcinoma/
carcinoma/purinergic P2/receptors/squamous cell. J Invest
Dermatol 121:315 ^327, 2003
B
asal cell carcinoma (BCC) and squamous cell carci-
noma (SCC) of the skin are the commonest malig-
nancies in White people, accounting for more than
95% of non-melanoma skin cancers (NMSC) (Mill-
er andWeinstock, 1994). The incidence of NMSC has
risen signi¢cantly over the last 10 y (Holme et al, 2000). An esti-
mated 2.75 million cases of NMSC are diagnosed per year world-
wide (Strom and Yamamura, 1997), with approximately one mil-
lion cases per year diagnosed in the USA (Miller andWeinstock,
1994). Multiple treatment modalities are available for NMSC, and
surgical management is the most common approach. In patients
with multiple lesions or in cases of tumors on di⁄cult locations
(e.g., eyelids or lips), surgery can cause signi¢cant dis¢gurement.
Topical drug treatment is indicated for super¢cial cutaneous neo-
plasms, which because of their multiplicity and involvement of
large surfaces are di⁄cult to treat with other methods. The pur-
pose of this study was to investigate whether purinergic receptors
could represent a suitable target for drug treatment of NMSC.
There is increasing evidence that purinergic signaling can have
long-term, trophic e¡ects in embryonic development, cell
growth, di¡erentiation, and proliferation (Abbracchio and Burn-
stock, 1998; Burnstock, 2001, 2002). Purinergic receptors are clas-
si¢ed into two groups: P1 receptors are selective for adenosine
and P2 receptors are selective for adenosine 50 -triphosphate
(ATP) and adenosine 50 -diphosphate (ADP), which act as extra-
cellular signaling molecules (Burnstock, 1978). P2 receptors are
divided into two main families: P2X and P2Y, based on molecu-
lar structure, transduction mechanisms and pharmacologic prop-
erties (Abbracchio and Burnstock, 1994). P2Y receptors are G-
protein-coupled and the principal signal transduction pathway
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involves phospholipase C, which leads to the formation of inosi-
tol 1,4,5-triphosphate (IP3) and mobilization of intracellular cal-
cium. IP3 regulates cell growth and DNA replication (Berridge,
1987). Seven subtypes of P2Yreceptors have been described so far
(King et al, 2000; Communi et al, 2001). In contrast, P2X recep-
tors are ligand-gated ion channels, and are activated by extracel-
lular ATP to elicit a £ow of cations (Naþ , Kþ , and Ca2þ ) across
the plasma membrane. Seven subtypes of P2X receptors are re-
cognized (Khakh et al, 2001a); all P2X1^7 subunits have been
cloned from mammalian species and are capable of assembling
into homomultimeric or heteromultimeric receptors (Torres et al,
1999).
There is growing evidence that ATP may act as an important
local messenger in the skin, particularly the epidermis. Purinergic
receptors are expressed on rat cutaneous keratinocytes and func-
tional roles in the regulation of proliferation, di¡erentiation, and
cell death have been proposed (Gr˛schel-Stewart et al, 1999). In
particular, P2X5 receptors are expressed on cells undergoing pro-
liferation and di¡erentiation, whereas P2X7 receptors are asso-
ciated with keratinized dead cells. P2Y2 receptors, found in the
basal layer of normal epidermis, are claimed to be involved in
keratinocyte proliferation (Dixon et al, 1999). P2Y1 receptors are
thought to be mitogenic in endothelial cells and P2Y2 and P2Y4
receptors stimulate vascular smooth muscle cell proliferation
(Burnstock, 2002).
There is evidence that there are functional purinergic receptors
in human malignant cell lines, including: MCF-7 breast cancer
cells (Wagsta¡ et al, 2000), endometrial cancer cell lines (Katzur
et al, 1999), prostate carcinoma cells (Janssens and Boeynaems,
2001), colorectal carcinoma cells (H˛pfner et al, 1998), ovarian can-
cer cells (Schultze-Mogasu et al, 2000), and HL-60 leukemia cells
(Conigrave et al, 2000).
This study demonstrates the spatially distinct distribution pat-
terns of di¡erent P2X and P2Y receptors in human BCC and
SCC as well as evidence for the actions of purinergic agonists
on cell proliferation and death in a SCC cell line. This suggests a
pathophysiologic role for these receptors and raises the possibility
that purinergic agonists are putative therapeutic agents.
MATERIALS AND METHODS
Tissues Frozen sections of 10 BCC (¢ve male, ¢ve female, mean age 71)
and four SCC (two male, two female, mean age 73) were examined in this
study. Ethics Committee Approval was obtained to harvest human NMSC
samples from consenting patients. The di⁄culty of obtaining fresh human
tissue for frozen sections led to the development of a special method to
allow staining of P2X5 and P2X7 receptors in para⁄n sections. Para⁄n
blocks of a BCC and SCC belonging to a collection at Mount Vernon
Hospital were examined.
Tissue was frozen in isopentane precooled in liquid nitrogen. Blocks
were sectioned at 10 mm on a cryostat (Reichert Jung CM1800), collected
on gelatin-coated slides and air-dried at room temperature. The slides were
stored at ^201C.
Antibodies The immunogens used for production of polyclonal P2X5
and P2X7 antibodies were synthetic peptides corresponding to 15
receptor-type-speci¢c amino acids in the intracellular C-termini of the
cloned rat and human P2X receptors, as described previously (Gr˛schel-
Stewart et al, 1999, Oglesby et al, 1999). The polyclonal antibodies were
raised by multiple monthly injections of New Zealand rabbits with the
peptides (performed by Research Genetics, Huntsville, Alabama). P2X5
and P2X7 antibodies (provided by Roche Bioscience, Palo Alto,
California) were kept frozen at a stock concentration of 1 mg per mL.
Polyclonal anti-P2Y1, P2Y2, and P2Y4 receptor antibodies were obtained
from Alomone Laboratories (Jerusalem, Israel), and corresponded to the
third extracellular loop of the P2Y1 (amino acids 242^258), P2Y2 (amino
acids 227^244), and P2Y4 receptor (amino acids 337^350) and were also
raised in rabbits. Antibodies were kept frozen at a stock concentration of
0.6 mg per mL (P2Y1, P2Y2) and 0.3 mg per mL (P2Y4). PCNA^
(monoclonal anti-proliferating cell nuclear antigen, clone PC10, raised in
mouse ascites £uid; Sigma, Poole, UK) is a marker for proliferation
(Miyagawa et al, 1989). Active caspase-3 is part of the apoptotic machinery
of the cell and is expressed in terminally di¡erentiating keratinocytes (Weil
et al, 1999). Active caspase-3 (Abcam, Cambridge, UK) antibody was raised
in rabbit.
Immunohistochemical methods for frozen sections For
immunostaining of cryostat sections, the avidin^biotin technique was
used according to a revised protocol (Llewellyn-Smith et al, 1993). Air-
dried sections were ¢xed for 2 min in 4% formaldehyde in 0.1 M
phosphate bu¡er, containing 0.2% of a saturated solution of picric acid
(pH 7.4). Endogenous peroxidase was blocked for 10 min with 50%
methanol containing 0.4% hydrogen peroxide. Nonspeci¢c binding sites
were blocked by a 20 min preincubation in 10% normal horse serum in
0.1 M phosphate bu¡er, containing 0.05% merthiolate (Sigma), followed
by incubation with the primary antibodies diluted to 1:100 or 1:200 in
antibody diluent (10% normal horse serum in PBSþ 2.5% sodium
chloride (NaCl) at 41C overnight. Subsequently, the sections were
incubated with biotinylated donkey anti-rabbit IgG (Jackson
ImmunoResearch Laboratory,West Grove, Pennsylvania) diluted to 1:500
in 1% normal horse serum in PBS for 30 min, followed by ExtrAvidin
peroxidase conjugate (Sigma) diluted to 1:1000 in PBS for 30 min at room
temperature. After a wash step, a nickel-diaminobenzidine enhancement
technique was used to visualize the reaction product. Sections were
washed three times with PBS after each of the above steps except after
preincubation with 10% normal horse serum. After the last wash, sections
were dehydrated twice in isopropanol and mounted with EUKITT (BDH
Laboratory Supplies, Poole, UK).
Controls for immunohistochemical method in frozen
sections Control experiments were carried out with primary antibodies
omitted from the staining procedure or the primary antibodies
preabsorbed with the corresponding peptides.
Double labeling of P2X7 receptor antibody with either terminal
deoxynucleotidyl transferase-mediated deoxyuridine triphosphate
nick end-labeling (TUNEL) or anti-human caspase 3 TUNEL
was performed using a kit (Boehringer Mannheim, Germany). TUNEL
identi¢es cells undergoing apoptosis by labeling nuclear DNA fragments
that have been cleaved during apoptosis (Gavrieli et al, 1992). Sections
were ¢xed and incubated with the P2X7 receptor antibody overnight as
described above. Then either the TUNEL or the anti-caspase 3 protocol
were followed.
For double labeling with TUNEL, sections were washed in PBS and
then incubated with the TUNEL reaction mixture for 1 h at 371C; then
for 1 h with biotinylated donkey anti-rabbit antibody at a concentration of
1:500; then for 1 h with streptavidinTexas red (Amersham International Plc,
Amersham, UK) at a concentration of 1:200. Sections were washed three
times with PBS after each of the above steps and at the end of the
staining procedure mounted in Citi£uor (Citi£uor Ltd, Leicester, UK).
For double labeling with anti-caspase-3, sections were washed in PBS
and then were incubated with biotinylated donkey anti-rabbit IgG
(Jackson ImmunoResearch Laboratory) diluted to 1:500 in 1% normal
horse serum in PBS for 1 h, followed by ExtrAvidin peroxidase conjugate
(Sigma) diluted to 1:1500 in PBS for 1 h, tyramide ampli¢cation for 8 min
(Tyramide Ampli¢cation Kit, NEN Life Science Products, Boston,
Massachusetts) and then streptavidin Texas red, diluted 1:200 in PBS-
merthiolate for 10 min. Sections were washed three times in PBS after
each of the above steps. Sections were preincubated for 20 min in 10%
normal goat serum and then incubated at room temperature for 2 h with
rabbit anti-human active caspase-3 (Abcam). Sections were washed and
incubated with the directly labeled secondary antibody, Oregon-green-
labeled goat-anti-rabbit IgG (Jackson ImmunoResearch Laboratory),
diluted 1:100 for 45 min. Sections were washed and mounted in Citi£uor.
Double labeling of P2Y2 receptor antibody with PCNA Sections
were ¢xed and incubated with P2Y2 antibody diluted 1:100 overnight as
described above. After a wash step, biotinylated donkey anti-rabbit IgG
antibody, diluted 1:500 in 1% normal horse serum in PBS, was then
applied for 1 h followed by streptavidin Texas red, diluted 1:200 in PBS-
merthiolate for 1 h at room temperature. Sections were preincubated for
30 min with 10% normal goat serum diluted in 0.1 M phosphate bu¡er,
containing 0.05% merthiolate (Sigma), and then incubated for 2 h at
room temperature with PCNA antibody (monoclonal anti-proliferating
cell nuclear antigen, clone PC10, raised in mouse ascites £uid; Sigma)
diluted 1:1000. After a wash step, the directly labeled secondary antibody
goat anti-mouse £uorescein isothiocyanate (Nordic Immunological
Laboratories, Tilburg, the Netherlands) was applied at a dilution of 1:200
for 1 h and then sections were washed and mounted in Citi£uor.
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Immunohistochemical method for para⁄n sections The method
below was an adaptation of the routine method used for
immunohistochemistry in para⁄n sections at The RAFT Institute,
Mount Vernon Hospital, Northwood (Middlesex, UK) and was
developed by Elizabeth Clayton, Histology Department, RAFT.
Microwave antigen retrieval was used for the visualization of both P2X5
and P2X7 receptors in para⁄n sections. Para⁄n blocks were sectioned at 4
mm on a Reichert-Jung Microtome, and sections were taken on Snowcoat
Extra slides (Surgipath, St Neots, Cambs, UK). The slides were then dried
in an oven for 2 h at 601C. P2X7 receptors were demonstrated using a
routine streptavidin alkaline phosphatase method and a Vector Red ¢nal
substrate system (Vector Laboratories, Peterborough, UK). P2X5 receptors
were demonstrated via tyramide ampli¢cation and a nickeldiamino-
benzidine ¢nal substrate system.
All histologic solvents, bu¡ered formal saline, toluene, xylene and
alcohol were supplied by Genta Medical (York, UK). Sections were
dewaxed and rehydrated using xylene and graded concentrations of
industrial methylated spirits, then washed in running tap water for 5 min
Sections were microwaved (Daewoo 800 W domestic microwave) at full
power in a plastic rack for 10 min in a covered but not closed container
¢lled with 400 mL 1 mM ethylenediamine tetraacetic acid at pH 8.0 and
then immediately washed in cold tap water for 2 to 3 min.
Sections were ringed with a wax pen and placed in a humidi¢cation
chamber for the application of immunoreagents. After incubation with
each immunoreagent, all slides were rinsed o¡ with a wash bottle ¢lled
with Tris-bu¡ered saline (TBS) containing Tween 20 (two drops Tween
per 500 mL of TBS) (TBSþT), placed in a slide rack and put in a fresh
bath of TBSþT on a magnetic stirrer for 15 min. This step was crucial in
order to reduce background staining.
Method for P2X5 receptor antibody immunostaining in para⁄n
sections Endogenous peroxidases were blocked using a 3% hydrogen
peroxide solution in methanol containing 0.3% sodium azide for 30 min.
Sections were washed in running tap water for 2 to 3 min and then placed
in a bath of 50 mM TBS (50 mM Trisþ150 mM NaCl pH 7.6). Sections
were incubated with one drop of Avidin D blocking solution for 15 min
(Avidin Biotin Blocking Kit SP200, Vector Laboratories). This was then
£icked o¡ and rinsed with TBSþT. One drop of the Biotin blocking
solution was then applied for 15 min (Avidin Biotin Blocking Kit SP200,
Vector Laboratories). Sections were washed with TBSþT and 100 mL 1:5
normal swine serum diluted in DAKO ChemMate antibody diluent
(DAKO S2022, DAKO, Ely, UK) was then applied to each section for 30
min. Excess swine serum was £icked o¡ the slides and the primary P2X5
receptor antibody (diluted 1:600 in DAKO ChemMate diluent) was applied
for 15 min.
The DAKO CSA kit was used for all subsequent layers as per kit
instructions (DAKO Catalyzed Serum Ampli¢cation system K1500 with
biotinylated anti-rabbit secondary antibody (DAKO K1498); DAKO).
After primary antibody incubation and washing, sections were incubated
with 100 mL biotinylated anti-rabbit antibody (prediluted from the kit)
for 15 min (solution 4). After washing with TBSþT, 100 mL of avidin^
biotin complex solution (prepared 30 min prior to use (solutions 5^7))
was applied for 15 min. After washing with TBSþT, 100 mL of tyramide
ampli¢cation solution was applied for 15 min (solution 8). After a wash
step with TBSþT, 100 mL of streptavidin-peroxidase reagent was applied
for 15 min (solution 9). Following washing with TBSþT, the nickel-
diaminobenzidine substrate chromogen was applied for 5 min. P2X5
receptors appeared brown and the intensity of the chromogen was
checked under the microscope before washing slides in running tap water.
Method for P2X7 receptor antibody immunostaining in para⁄n
sections The streptavidin alkaline phosphatase method was used to
demonstrate P2X7 receptors in para⁄n sections. This method provided
staining with a striking contrast for positive and negative reactions, was
£uorescent when looking for low level expression and caused no
confusion with endogenous pigments.
Endogenous alkaline phosphatase was blocked by a 20 min incubation in
a bath of 20% acetic acid solution. Sections were washed and incubated
¢rst with avidin D blocking solution (Vector Laboratories), then biotin
blocking solution (Vector Laboratories), and then 1:5 normal swine serum
as above. One hundred microliters of P2X7 receptor antibody, diluted 1:100
was applied for 1 h at room temperature or overnight at 41C.
After a wash step with TBSþT, 100 mL of biotinylated anti-rabbit
antibody (DAKO E0353), diluted 1:200 in DAKO ChemMate diluent
(DAKO), was applied for 30 min. After washing in TBSþT, 100 mL of
streptavidin alkaline phosphatase (Vector SA5100) diluted 1:200 in DAKO
ChemMate diluent, was applied for 30 min After washing in TBSþT,
Vector Red substrate (Vector Alkaline phosphatase substrate, SK5100)
made up in 200 mM Tris^HCl (pH 8.2) was applied for 10 min. P2X7
receptor staining appeared bright pink, the intensity of the chromogen
was checked under the microscope prior to washing the slides in running
tap water for 2 to 3 min.
Counterstaining Nuclei were counterstained blue with Harris
hematoxylin for 10 to 30 s and all sections were subsequently dehydrated,
cleared, and mounted.
Controls for immunohistochemical method in para⁄n
sections Negative controls were used: either diluent only or 1:5 normal
swine serum were substituted for the P2X5 or P2X7 receptor antibody at
an equivalent dilution. Numerous test sections showed no reaction with
either the diluent alone or with the added normal swine serum; therefore,
subsequently, the ChemMate diluent was used alone as a negative control.
Photography The results were analyzed using a Zeiss Axioplan high
de¢nition light microscope (Oberkochen, Germany) mounted with a
Leica DC 200 digital camera (Heerbrugg, Switzerland).
A431 cell line This human epidermal SCC cell line was purchased from
the European Collection of Cell Cultures (ECACC no. 85090402). Cells
were grown at 371C in a humidi¢ed 5% CO2 atmosphere. Cultures were
grown on plastic in Dulbecco minimal Eagle’s medium supplemented with
10% fetal calf serum, penicillin, streptomycin, and L-glutamine. Cells were
disaggregated at 70% con£uency with trypsin/ethylenediamine tetraacetic
acid and seeded at 1  104 cells per well in a 96 well plate. This seeding
density gave the best growth curve over a 72 h period.
Proliferation assay Twenty-four hours after seeding into 96 well plates,
medium was gently aspirated from culture wells and P2 receptor subtype
agonists were applied to the A431 cells, diluted in medium. These were
obtained from Sigma and included: ATP; uridine 50 -triphosphate (UTP),
P2Y2 receptor agonist (von Kˇgelgen andWetter, 2000); adenosine 50 -O-
(3-thiotriphosphate) (ATPgS), P2X5 receptor agonist (Khakh et al, 2000);
20 - 30 -O-(4 -benzoyl-benzoyl) adenosine 50 -triphosphate (BzATP), P2X7
receptor agonist (Khakh et al, 2001a); and 2-methylthioadenosine 50 -
diphosphate (2MeSADP), P2Y1 receptor agonist (von Kˇgelgen and
Wetter, 2000). The pH of the drug solutions prepared in the culture
medium was 7.0.
Changes in cell number were quanti¢ed via a colorimetric assay using
crystal violet (Gillies et al, 1986; Kueng et al, 1989) and read using a
spectrophotometric plate reader (Model 550, Microplate Manager 4.0 Bio-
Rad Laboratories, Inc. Hercules, CA USA) at 0, 24, 48, and 72 h after
addition of drugs. For the colorimetric assay, a solution of 0.5 g crystal
violet, 0.85 g NaCl, 5 mL 10% formal saline, 50 mL absolute ethanol,
45 mL distilled H2O was used. Medium was gently aspirated from wells
of a 96 well plate and 100 mL of the colorimetric assay mixture was added
to each well and incubated at room temperature for 10 min. This mixture
allowed simultaneous ¢xation of cells and penetration of the crystal
violet dye into the cells. After washing three times in PBS, 33% acetic
acid was used to elute color from cells and optical density was read at
595 nm using the spectrophotometric plate reader. The changes in cell
number identi¢ed by the crystal violet assay were validated at least once
for each drug set by doing actual cell counts with a hemocytometer. To
con¢rm that the optical density of the wells correlated with cell numbers,
a control assay was performed for each experiment, where known numbers
of cells were seeded in ascending seeding densities and the plate read as
soon as cells had attached. Cell number versus optical density was plotted.
The R2 value of the trend line was always greater than 0.98 (data not
shown).
Statistical analysis Each proliferation assay experiment was repeated an
average of eight times, each with triplicate samples. Data analysis was
performed using Microsoft Excel 97 and GraphPad Prism 3.0 software.
One-way analysis of variance (ANOVA) and Bonferroni’s multiple
comparison test were carried out between groups.
RESULTS
P2X5, P2X7, P2Y1, P2Y2, and P2Y4 receptors were expressed
in frozen sections of BCC P2X5 receptors were heavily
expressed in tumor cells of BCC, but slightly less heavily than
in the epidermis (Fig 1a). At high power, P2X5 receptors were
expressed within the cell cytoplasm of tumor cells and the level
of staining intensity in tumor cells was comparable with that seen
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in basal cells within the epidermis. In the central area of the
tumor, staining was absent (Fig 1a). P2X7 receptors were
expressed in the necrotic center of nodular BCC (Fig 1b).
Although nonspeci¢c staining in necrotic areas does occur, this
staining disappeared on preabsorption of the P2X7 primary
antibody, suggesting that it was speci¢c. At higher
magni¢cation, the staining was seen to be associated with mast
cells, macrophages, and swollen ¢broblasts in the stroma
surrounding the tumor. In normal skin, P2X7 receptors are
found in the stratum corneum. It was noticeable that in the
more normal areas of skin that P2X7 receptors were present, but
in the area immediately over the BCC, the expression of P2X7
receptors disappeared (Fig 1c).
P2Y1 receptors were expressed in the stroma surrounding the
tumor, but not within the tumor cells (Fig 1d). P2Y2 receptors
(Fig 1e) and P2Y4 receptors (Fig 1f) were expressed within the
tumor but not in the surrounding stromal matrix. Both the
omission of the primary antibody and preabsorption with
corresponding peptides were performed as controls in sections
of BCC. There was no immunoreaction when the primary
antibody was omitted. The immunoreaction was abolished after
preabsorption of the P2X5 (Fig 1g), P2X7 (Fig 1h), P2Y1 (Fig 1i),
P2Y2 (Fig 1j), and P2Y4 receptor antibodies (Fig 1k) with the
corresponding peptides, con¢rming the speci¢city of the
immunoreaction.
P2X5, P2X7, P2Y1, and P2Y2 receptors were expressed in
frozen sections of SCC P2X5 receptors were more heavily
expressed in the tumor cells than in the cells of the surrounding
epidermis and P2X5 receptors were located speci¢cally on the cell
Figure1. P2X5, P2X7, P2Y1, P2Y2, and
P2Y4 receptor staining in BCC. (a) P2X5 re-
ceptors were heavily expressed in tumor (T), but
slightly less heavily than in the epidermis (ar-
row). In the central area of the tumor, staining
was absent. Scale bar¼ 200 mm. (b) P2X7 recep-
tors were expressed in the necrotic center of the
BCC (arrowhead), as well as in the stratum cor-
neum (arrow). Scale bar¼ 200 mm. (c) P2X7 re-
ceptors were found in the stratum corneum in
the more normal areas of skin (arrows), but in
the area immediately over the BCC, the expres-
sion of P2X7 receptors disappeared. Scale
bar¼175 mm. (d) P2Y1 receptors were expressed
in the basal layer of the epidermis (arrow) over-
lying the tumor, and in the stroma (S) sur-
rounding the tumor (T), but not within the
tumor itself. Scale bar¼100 mm. (e) P2Y2 recep-
tors were expressed in the basal layer of the epi-
dermis (arrow), and within tumor (T) and not in
the surrounding stromal matrix (S). There was
some nuclear staining within the epidermis
Scale bar¼100 mm. (f) P2Y4 receptors were
faintly expressed in the basal layer of the epider-
mis (arrow), and more strongly within tumor
(T) and not in the surrounding stromal matrix
(S). There was some nuclear staining within the
epidermis. Scale bar¼100 mm.The immunoreac-
tion was abolished after preabsorption of the (g)
P2X5, (h) P2X7, (i) P2Y1, (j) P2Y2, and (k) P2Y4
receptor antibodies with the corresponding
peptides, con¢rming the speci¢city of the im-
munoreaction. There was, however, some mela-
nin in the basal layer of the epidermis, which
could be distinguished from immunostaining
by its color. Scale bars: (g^k) 250 mm.
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membrane of the SCC cells (Fig 2a), rather than within the cell
cytoplasm as in BCC tumor cells. P2X7 receptors were strongly
expressed in the stratum corneum of the epidermis but only
weakly expressed in the nucleus of occasional tumor cells (Fig 2b).
P2Y1 receptors were strongly expressed within the stromal matrix
surrounding the tumor nests within the dermis, but not expressed
within the tumor (Fig 2c). P2Y2 receptors were strongly expressed
within the tumor, but not expressed within the surrounding
stromal matrix (Fig 2d). The P2Y2 receptor staining appears to be
both in the cell membrane and weakly in the nucleus of the tumor
cells. The SCC cells appear nonuniform in size and shape, with
vacuolation of the cytoplasm in some cells, which may explain
the nonuniformity of P2Y2 staining in some tumor cells. P2Y4
receptors were not expressed in the SCC’S examined.
Both the omission of the primary antibody and preabsorption
with corresponding peptides were performed as controls in
sections of SCC. There was no immunoreaction when the
primary antibody was omitted. The immunoreaction was
abolished after preabsorption of the P2X5 (Fig 2e), P2X7
(Fig 2f), P2Y1 (Fig 2g), and P2Y2 receptor antibodies (Fig 2h)
with the corresponding peptides, con¢rming the speci¢city of
the immunoreaction. The distribution of P2X and P2Y
receptors in both BCC and SCC is summarized in Table I. P2
receptor staining in normal skin is described in detail in Greig
et al (2003).
Double labeling of P2X7 receptors with TUNEL or anti-
human caspase-3 showed colocalization, and double
labeling of P2Y2 receptors with PCNA showed overlap in
NMSC Double labeling of P2X7 receptors and TUNEL in the
center of a nodular BCC showed colocalization on cells
undergoing apoptosis, with P2X7 receptors also expressed
in cellular fragments (Fig 3a). Double labeling with P2X7
receptors and anti-human caspase-3, showed colocalization in
the nuclei of cells within the tumor nests of a SCC (Fig 3b).
Double labeling with P2Y2 receptors (red) and PCNA (green)
(Fig 3c) showed that there was much proliferative activity within
SCC tumor nests and that there was overlap between the cells
expressing PCNA and P2Y2 receptors.
P2X5 and P2X7 receptors were expressed in para⁄n sections
of BCC and SCC The immunostaining of para⁄n sections
showed essentially the same distribution as that in frozen
sections, although more detail of the cellular and subcellular
composition was visible. The development of this method also
allowed us to look at archive material of para⁄n sections of
di¡erent tumor subtypes. P2X5 and P2X7 receptors were
examined because they are involved in early keratinocyte
di¡erentiation and terminal keratinocyte di¡erentiation/
apoptosis, respectively. Para⁄n sections of BCC were grouped as
follows: 11 nodular (including three solid subtypes), nine
super¢cial multifocal, and 24 in¢ltrative (morpheic). Of the 24
in¢ltrative BCC, seven represented a subgroup of ‘‘horrifying
BCC’’ (Horlock et al, 1998), which were clinically locally
aggressive and deeply invasive. The distribution of P2X5 and
P2X7 receptors within subgroups of BCC is summarized in
Table II.
In nodular BCC, P2X5 receptor staining (brown) was present
both in the tumor (in the cell cytoplasm), but also in cells of the
surrounding stromal matrix (Fig 4a). These positive stromal
cells were likely to be endothelial cells, seen at higher power
in association with capillaries. P2X7 receptors (pink) were
Figure 2. P2X5, P2X7, P2Y1, and P2Y2 re-
ceptor staining in SCC. (a) P2X5 receptors
were more heavily expressed on tumor cell
membranes (arrows) than on the cells of the sur-
rounding epidermis. Scale bar¼ 30 mm. (b) P2X7
receptors were strongly expressed in the stratum
corneum of the epidermis and only weakly ex-
pressed within the tumor (T). Scale bar¼ 30 mm.
(c) P2Y1 receptors were strongly expressed with-
in the stromal matrix (S) surrounding the nests
of tumor (T) within the dermis, but not ex-
pressed within the tumor itself. Scale bar¼ 50
mm. (d) P2Y2 receptors were strongly expressed
within the tumor (T) within the dermis, but
not expressed within the surrounding stromal
matrix (S). Scale bar¼ 50 mm.The immunoreac-
tion was abolished after preabsorption of the (e)
P2X5, (f) P2X7, (g) P2Y1, and (h) P2Y2 receptor
antibodies with the corresponding peptides,
con¢rming the speci¢city of the immunoreac-
tion.Scale bars: (g^j) 200 mm.
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expressed in the necrotic center of nodular BCC (Fig 4b) the
same as in frozen sections. In super¢cial multifocal BCC, P2X5
receptors were expressed in a patchy fashion throughout tumor
nests mostly in the tumor cell cytoplasm (Fig 4c). P2X7
receptors were weakly expressed in the nucleus of occasional
tumor cells (Fig 4d). In in¢ltrative BCC, the P2X5 receptor
staining was di¡erent in cells at the edge of the tumor nest,
from cells in the center (Fig 4e). Cells at the edge had positive
staining in the plasma membrane, and this staining appeared to
be polarized to the surface of the cells that were in contact with
Table I. Distribution of P2X and P2Y receptor subtypes in normal skin, BCC and SCC
Receptor Normal skin BCC SCC
P2X5 Weaker in basal layer, strong staining in stratum
spinosum and granular layer keratinocytes
Tumor cell cytoplasm, endothelial cells Tumor cell membranes, endothelial cells
P2X7 Stratum corneum Necrotic areas within tumor, mast cells,
macrophages and ¢broblasts
Nucleus of occasional tumor cells
P2Y1 Basal epidermal keratinocytes Stroma Stroma
P2Y2 Basal epidermal keratinocytes Tumor cell cytoplasm Tumor cell cytoplasm
P2Y4 Weak in epidermis Tumor cell cytoplasm No staining
Figure 3. Double labeling of P2X7 receptors
with TUNEL and anti-human caspase-3 and
P2Y2 receptors with PCNA. (a) Double label-
ing of P2X7 receptors (red) and TUNEL (green)
in the center of a nodular BCC showed colocali-
zation of cells undergoing apoptosis, with P2X7
receptors also expressed in cellular fragments.
Scale bar¼ 40 mm. (b) Double labeling with P2X7
receptors (red) and anti-human caspase 3 (green),
showed colocalization in the nuclei (yellow) of
SCC cells within a tumor nest.Scale bar¼ 50 mm.
(c) Double labeling with P2Y2 receptors (red) and
PCNA (green nuclear staining) showed that there
was overlap between SCC cells expressing PCNA
and P2Y2 receptors. Scale bar¼ 50 mm.
Table II. Analysis of P2X5 and P2X7 receptor distribution in para⁄n sections of BCC subgroups
P2X5
þ/ P2X5
^/ P2X5
þ/ P2X5
^/
BCC subtype P2X5
þ P2X7
þ P2X7
þ P2X7
^ P2X7
^ P2X7
þ
Nodular (11) 7 4 4 4 3 0
Super¢cial multifocal (9) 5 3 3 4 2 0
In¢ltrative (17) 14 10 9 2 5 1
Horrifying (7) 4 1 1 3 3 0
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the basement membrane surrounding the tumor nest. In contrast,
cells in the center of the tumor nest had positive staining for
P2X5 receptors in the cell cytoplasm, as seen in nodular (Fig 4a)
and super¢cial multifocal BCC (Fig 4c). P2X7 receptor
immunoreactivity in in¢ltrative BCC was mainly in shrunken,
condensed, possibly apoptotic nuclei near the center of tumor
nests (Fig 4f). In ‘‘horrifying BCC’’, a locally aggressive and
deeply invasive subgroup of in¢ltrative BCC, P2X5 receptors
were seen in the cytoplasm of tumor cells in association with
numerous cells undergoing mitosis (Fig 4g). In ‘‘horrifying
BCC’’, P2X7 receptors were expressed in the nucleus of
numerous cells but unlike in in¢ltrative BCC the nuclei were
not condensed or apoptotic (Fig 4h).
SCC were subclassi¢ed as follows: ¢ve Bowen’s disease
(carcinomas in situ), four di¡erentiated SCC, and ¢ve invasive
SCC. Two basisquamous (metaplastic) carcinomas, showing
characteristics of both BCC and SCC, were also analyzed
immunohistochemically. The distribution of P2X5 and P2X7
receptors within subgroups of SCC is summarized inTable III.
All examples of Bowen’s disease (SCC in situ) examined were
positive for P2X5 receptors (Table III). The staining was mainly
in the cytoplasm and was much more intense than in the
surrounding normal epidermis (Fig 5a). There were also positive
cells staining for P2X5 receptors within the dermis (Fig 5a),
which were likely to be endothelial cells in association with
capillaries. P2X7 receptors were expressed in Civatte bodies
(apoptotic keratinocytes) within the tumor (Fig 5b). All four
well-di¡erentiated SCC were positive for both P2X5 and P2X7
receptors (Table III). In well-di¡erentiated SCC, P2X5 receptors
were heavily expressed throughout the tumor, in the tumor cell
cytoplasm (Fig 5c). P2X5 receptors were heavily expressed at the
edges of keratin pearls, but were less intensely expressed in the
more di¡erentiated central areas of keratin pearls. In contrast,
P2X7 receptors were only expressed in the center of keratin
Figure 4. P2X5 and P2X7 receptors are ex-
pressed in para⁄n sections of di¡erent sub-
types of BCC; sections counterstained with
hematoxylin to stain nuclei blue. (a,b) Nodular
BCC. (a) P2X5 receptors (brown) were expressed
within the tumor (T) and cells of the stromal
matrix also show strong labeling (arrow). The
staining was uniform in nature throughout each
tumor nest and mainly in the cell cytoplasm.
Scale bar¼ 50 mm. (b) P2X7 receptors (pink) were
expressed in the necrotic center of nodular BCC
(arrowhead) as in the frozen sections. They were
also expressed on in£ammatory cells (arrow) sur-
rounding the tumor (T). Scale bar¼ 50 mm. (c,d)
Super¢cial multifocal BCC. (c) P2X5 receptors
(brown) were expressed in a patchy fashion
throughout tumor nests mostly in the tumor cell
cytoplasm. Scale bar¼ 25 mm. (d) P2X7 receptors
(pink) were weakly expressed in the nucleus
of occasional tumor cells (arrows). Scale bar¼
25 mm. (e,f ) In¢ltrative BCC (e) P2X5 receptors
(brown) were expressed in both the basal (arrows)
and suprabasal layers of the tumor. Scale bar¼
50 mm. (f) P2X7 receptor immunoreactivity
(pink) was seen to be nuclear or perinuclear (ar-
rows), often in cells towards the center of a tumor
nest. The stained nuclei were condensed and
shrunken away from surrounding tissue. Scale
bar¼ 50 mm. (g,h) ‘‘Horrifying BCC’’, a subgroup
of the in¢ltrative type of BCC, which is locally
aggressive, and deeply invasive. (g) P2X5 recep-
tors (brown) were seen in the cytoplasm of tu-
mor cells in association with numerous cells
undergoing mitosis (arrows). Scale bar¼ 25 mm.
(h) P2X7 receptors (pink) were expressed in the
nucleus of numerous cells (arrows) but unlike in-
¢ltrative BCC (f) the nuclei were not condensed.
Scale bar¼ 25 mm.
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pearls in more di¡erentiated cells and in areas where necrosis had
occurred (Fig 5d). In invasive SCC, P2X5 receptors were more
heavily expressed in the invasive tumor compared with normal
areas of epidermis (Fig 5e). In invasive SCC, P2X7 receptor
immunoreactivity was seen within shrunken, pyknotic,
apoptotic-looking nuclei, often in cells towards the center of a
tumor nest (Fig 5f). In basisquamous (metaplastic) carcinomas,
P2X5 receptor labeling was found both in the tumor cell
Figure 5. P2X5 and P2X7 receptors are ex-
pressed in para⁄n sections of di¡erent sub-
types of SCC; sections counterstained with
hematoxylin to stain nuclei blue. (a,b) Bowen’s
disease (SCC in situ). (a) P2X5 receptors (brown)
were expressed within the tumor (T) and also in
cells of the stromal matrix. There was almost no
staining within the basal layer of the epidermis
(arrow). Scale bar¼ 50 mm. (b) P2X7 receptors
(pink) were expressed in Civatte bodies (apopto-
tic keratinocytesarrow) within the area of the
tumor. Scale bar¼ 50 mm. (c,d) Well-di¡erentiated
SCC. (c) P2X5 receptors (brown) were heavily
expressed throughout the tumor, especially in
areas where keratin pearls (asterisk) were form-
ing. The receptors were also found in the tumor
cell cytoplasm, but showed lower expression in
the more di¡erentiated areas of the keratin pearls
(asterisk). Scale bar¼ 50 mm. (d) P2X7 receptors
(pink) were only expressed in the center of ker-
atin pearls in the more di¡erentiated cells and in
areas where necrosis had occurred (arrow). Scale
bar¼ 50 mm. (e,f ) Invasive SCC. (e) P2X5 recep-
tors (brown) were more heavily expressed in the
invasive tumor (T) compared with the more
normal areas of epidermis nearby (double arrows).
Scale bar¼100 mm. (f) P2X7 receptor immunor-
eactivity was seen in the nucleus (arrow), often in
cells towards the center of a tumor nest. Scale
bar¼100 mm. (g,h) Basisquamous (metaplastic) carci-
noma. (g) P2X5 receptors (brown) were seen in
all tumor cells. Scale bar¼ 50 mm. (h) P2X7 re-
ceptors (pink) were expressed in nuclei (arrows)
that were condensed and possibly apoptotic.
Scale bar¼ 50 mm.
Table III. Analysis of P2X5 and P2X7 receptor distribution in para⁄n sections of SCC subgroups
P2X5
þ/ P2X5
^/ P2X5
þ/ P2X5
^/
SCC subtype P2X5
þ P2X7
þ P2X7
þ P2X7
^ P2X7
^ P2X7
þ
Bowen’s disease (carcinoma in situ) (5) 5 3 3 0 2 0
Di¡erentiated (4) 4 4 4 0 0 0
Invasive (5) 5 3 3 0 2 0
Basisquamous (metaplastic) (2) 2 2 2 0 0 0
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membrane and within the cytoplasm (Fig 5g). P2X7 receptors
were expressed in condensed nuclei, which were possibly
apoptotic (Fig 5h). Both basisquamous carcinomas examined
were positive for P2X5 and P2X7 receptors (Table III).
P2X5, P2X7, P2Y1, and P2Y2 receptors were expressed in
A431 cells grown in culture P2X5 (Fig 6a), P2X7 (Fig 6b),
P2Y1 (Fig 6c), and P2Y2 receptors (Fig 6d) were expressed on
A431 cells on the cell membranes. Both the omission of the
primary antibody and preabsorption with corresponding peptides
were performed as controls. There was no immunoreaction
when the primary antibody was omitted. Furthermore, the
immunoreaction was abolished after preabsorption of the
P2X5, P2X7, P2Y1, and P2Y2 receptor antibodies with the
corresponding peptides, con¢rming the speci¢city of the
immunoreaction.
Actions of P2 receptors agonists on cell numbers of cultured
cutaneous SCC, A431 cells Low concentrations of ATP (10
mM) caused an increase in cell number, whereas high
concentrations of ATP (500^5000 mM) caused a signi¢cant
decrease (po0.001) in cell number at 48 h after application (Fig
7), with cells in the 5000 mMATP solution appearing rounded up
and dead (Fig 7e). Low concentrations of ATPgS (1^10 mM) and
high concentrations of UTP (1000 mM) caused an increase in cell
number, with UTP causing a signi¢cant e¡ect (po0.001). High
concentrations of ATP (500 mM) and ATPgS (100^500 mM)
caused a signi¢cant decrease (po0.001) in cell number, at 48 h
after drug application to A431 cells (Fig 8a). The P2X7 receptor
agonist, BzATP (500 mM) (Fig 8b) caused a signi¢cant reduction
in cell number (po0.001) and the P2Y1 receptor agonist,
2MeSADP (1^500 mM) (Fig 8c) caused a reduction in cell
number, which was not statistically signi¢cant.
DISCUSSION
In this study, we have obtained the ¢rst direct evidence for the
expression of P2X5, P2X7, P2Y1, and P2Y2 receptors in human
BCC and SCC, using immunohistochemistry and functional stu-
dies in vitro with the human SCC, A431 cell line. In vitro experi-
ments with A431 cells were used to give an indication of the
e¡ects of P2 receptor agonists on SCC cells in vivo, but further
experiments are needed to assess the e¡ects in tumors. Low con-
centrations of ATP increased A431 cell number. Previous work
with A431 cells has shown that micromolar range concentrations
of ATP are mitogenic for A431 cells (Huang et al, 1989) and in-
crease intracellular calcium levels (Gonzalez et al, 1988). ATP has
also been shown to activate cell proliferation in human ovarian
tumor cells (Popper and Batra, 1993) and in MCF-7 breast cancer
cells (Dixon et al, 1997). From our functional data in A431 cells,
UTP, the P2Y2 receptor agonist caused a signi¢cant increase
Figure 6. P2X5, P2X7, P2Y1, and P2Y2 receptor staining in SCC, A431 cells grown in culture. (a) P2X5, (b) P2X7, (c) P2Y1, and (d) P2Y2 receptor
immuno-labeling on the membranes of A431 cells. Scale bar¼ 20 mm.
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(po0.001) in proliferation. P2Y2 receptors were heavily expressed
in both BCC and SCC and there was overlap between cells ex-
pressing PCNA and P2Y2 receptors. The proportion of PCNA-
positive cells in SCC tumor nests was higher than in normal epi-
dermis.Where this increased expression of PCNAwas found, so
the expression of P2Y2 receptors was proportionally increased
compared with normal epidermis. Taken together, the PCNA
¢ndings further con¢rm our ¢ndings in the functional experi-
ments that P2Y2 receptors are likely to be involved in prolifera-
tion. Previous work has localized P2Y2 receptor mRNA in
human epidermal basal cells via in situ hybridization (Dixon et al,
1999). UTP has also been shown to cause proliferation of normal
keratinocytes (Dixon et al, 1999) and HaCaT cells (Lee et al, 2001).
Functional P2Y2 receptors have also been characterized on hu-
man ovarian cancer cells (Schultze-Mogasu et al, 2000), colorectal
carcinoma cells (H˛pfner et al, 1998), prostate carcinoma cells
(Janssens and Boeynaems, 2001), endometrial cancer cell lines
(Katzur et al, 1999), and MCF-7 breast cancer cells (Wagsta¡ et al,
2000).
In contrast, high concentrations of ATP and the P2X7 receptor
agonist, BzATP caused a signi¢cant decrease in A431 cell number
(po0.001).The concentrations of ATP used were anticipated to be
within the physiologic range because ATP physiologically re-
leased from nerves (Sperla¤ gh and Vizi, 1996), endothelial cells
(Bodin and Burnstock, 1998), and urothelial cells (Ferguson,
1999) can reach very high levels extracellularly (4 10^3 mM) be-
fore being broken down by ectoenzymes. P2X7 receptors were
heavily expressed in the necrotic center of nodular BCC and co-
localized with TUNEL labeling. They were also expressed in
apoptotic cells in both in¢ltrative BCC and in SCC and P2X7
receptors colocalized with active caspase-3. The P2X7 receptor is
unlike other P2X receptors because it is a bifunctional molecule
that can be triggered by low concentrations of ATP to act as a
channel permeable to small cations, or at high concentrations
(4 100 mM), forms a cytolytic pore permeable to large hydrophi-
lic molecules up to 900 Da (Surprenant et al, 1996). The opening
of this pore results in the increase in intracellular cytosolic free
calcium ions, leading to cell death. The reduction in A431 cell
Figure 7. Change in cell number of SCC, A431 cells at 48 h after ATP application. At 48 h after application, low doses of ATP (10 mM) caused an
increase in cell number, whereas high doses of ATP (1000^5000 mM) (po0.001) caused a signi¢cant decrease. Results represent the mean of 26 experiments.
npo0.001 compared with control. Error bars represent mean 7 SEM. These e¡ects were shown also by the colony size and cell morphology. A431 cells
were stained with crystal violet and phase contrast micrographs were taken. (a) Controlcells grown in A431medium only; (b) 10 mMATP caused colonies
of A431 cells to appear visibly larger than in control wells; (c) 100 mM ATP caused no change in the colony size; (d) 1000 mM ATP and (e) 5000 mM ATP
both caused a marked decrease in colony size, with cells rounding up and dying in 5000 mM ATP. Scale bar¼150 mm.
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number with increasing concentrations of ATP or BzATP could
have resulted from either inhibition of proliferation or stimula-
tion of cell death; however, BzATP is established as a 10 to 30
times more potent agonist at P2X7 receptors than ATP, leading
to apoptosis (North, 2002). There is no published evidence that
P2X7 receptors mediate inhibition of cell proliferation.
The P2X7 receptor is involved in the release of interleukin-1b
(Ferrari et al, 1997) and the induction of cell death (Zheng et al,
1991; Ferrari et al, 1996). P2X7 receptors have been localized in
rat and human epidermis (Gr˛schel-Stewart et al, 1999; Greig
et al, 2003) and are also found on dendritic cells, macrophages,
and microglial cells, where high concentrations of extracellular
ATP can trigger apoptosis via these receptors and there is increas-
ing evidence that this process is dependent on the caspase signal-
ing cascade (Coutinho-Silva et al, 1999; Ferrari et al, 1999).
Extracellular ATP induces apoptosis and inhibits growth of col-
orectal carcinoma cells in culture (H˛pfner et al, 1999). ATP inhi-
bits growth in breast cancer cells (Spungin and Friedberg, 1993),
androgen-independent prostate carcinoma cells (Fang et al, 1992),
and Ehrlich tumor cells (Lasso de laVega et al, 1994).
BCC are slow-growing tumors with paradoxically high prolif-
erative activity. The slow growth has been previously explained
by a concurrent high apoptotic activity (Miller, 1991a, b). The in-
terpretation of BCC as a neoplasm with high apoptotic activity
has been supported by electron microscopy (Miller, 1991a, b) and
an end-labeling study (Mooney et al, 1995). From our analysis of
di¡erent subgroups of BCC in para⁄n section, it appears that in
moderately aggressive tumors, there is a high level of expression
of P2X7 receptors, but with increasing aggressiveness of tumor,
this is reduced. The 24 in¢ltrative BCC studied can be divided
into two groups: 17 in¢ltrative BCC and seven ‘‘horrifying
BCC’’. In 17 in¢ltrative BCC, 59% expressed P2X7 receptors but
only 14% of ‘‘horrifying BCC’’ expressed P2X7 receptors and
within this tumor, the receptor was expressed on most of the cells
within it, with positive cells not appearing to be apoptotic, in
contrast to the other group of in¢ltrative BCC analyzed. Re-
duced apoptosis may lead to unstable tissue kinetics, favoring an
increase in total cell numbers, which in tumors correspond to the
stage of cellular expansion. A reduction in apoptosis may be re-
sponsible for the preservation of genetically aberrant cells, favor-
ing neoplastic progression (Staibano et al, 1999). This may partly
explain the aggressive nature of these ‘‘horrifying BCC’’. Analysis
of para⁄n sections of SCC showed that P2X7 receptors were ex-
pressed in all the di¡erentiated tumors studied, but in only three
of ¢ve invasive SCC. This would suggest, despite the small sam-
ple size that more aggressive tumors also have reduced expression
of P2X7 receptors.
High concentrations of ATPgS, a potent P2X5 receptor ago-
nist, caused a signi¢cant decrease in cell number, at 48 h after
drug application to A431 cells. This may be because cells are with-
drawing from the cell cycle and di¡erentiating. There is evidence
from other tissues regarding the role of P2X5 receptors. In nor-
mal rat and human epidermis (Greig et al, 2003) P2X5 receptors
are found predominantly in di¡erentiating keratinocytes
(Gr˛schel-Stewart et al, 1999). In fetal rat skeletal muscle, P2X5
receptors are sequentially expressed during development (Ryten
et al, 2001). P2X5 receptors have been implicated in the regulation
of osteoblastic di¡erentiation and proliferation (Hoebertz et al,
2000) and in triggering the di¡erentiation of skeletal muscle sa-
tellite cells (Ryten et al, 2002). In para⁄n sections of SCC, P2X5
receptors were highly expressed in all subgroups of tumors, with
increased expression compared with the surrounding ‘‘normal’’
epidermis. P2X5 receptors were not found in the basal layer in
Bowen’s disease (carcinoma in situ), but only in the suprabasal,
di¡erentiated cell layers. P2X5 receptor staining in SCC was on
the cell membrane, whereas in BCC, the receptors were expressed
in the cell cytoplasm. In basisquamous (metaplastic) carcinomas,
P2X5 receptor labeling was found both in the tumor cell mem-
brane and within the cytoplasm, re£ecting the dual di¡erentia-
tion of this tumor subtype. The cytoplasmic distribution and
Figure 8. Comparison of e¡ect of P2 agonists at 48 h after drug ap-
plication to A431 cells. (a) At 48 h after application, ATP (1^10 mM),
ATPgS (1^10 mM), and UTP (1000 mM) (po0.001) caused an increase in
cell number of primary human keratinocyte cultures, whereas ATPgS
(100^500 mM) (po0.001) and ATP (500 mM) (po0.001) caused a signi¢cant
decrease in cell number. Results represent the mean of eight experiments.
npo0.001 compared with control. (b) BzATP (P2X7 receptor subtype ago-
nist) (500 mM) caused a signi¢cant reduction in cell number (npo0.001).
Results represent the mean of eight experiments. npo0.001 compared with
control. (c) 2MeSADP (P2Y1 receptor subtype agonist) (1^500 mM) caused
a reduction in cell number, whichwas not signi¢cant. Results represent the
mean of eight experiments. Error bars represent mean7 SEM.
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level of staining intensity of P2X5 receptors in BCC tumor cells
was comparable with that seen in basal cells within the normal
epidermis, which may re£ect the basal cell origin of these tumors.
In this study, P2X5 receptors were present either or both in the
cell membrane and in the cytoplasm. Studies using P2X2 recep-
tors tagged with green £uorescent protein in hippocampal neu-
rons have con¢rmed that P2X receptors can have both a
cytoplasmic and cell membrane distribution (Khakh et al,
2001b). P2X1 receptors tagged with green £uorescent protein
(Dutton et al, 2000; Li et al, 2000) and native P2X1 receptors (En-
nion and Evans, 2001) have also been shown to undergo interna-
lization during application of ATP or ab-meATP to the cell. It
has been proposed that P2X1 receptor internalization is part of
the cellular recycling of receptors and that it is part of the process
of receptor activation, inactivation, internalization, and recovery
(Ennion and Evans, 2001). It is likely that P2X5 receptors also
take part in these processes and this is why they have been loca-
lized both on the cell membrane and in the cell cytoplasm.
In para⁄n sections of BCC, P2X5 receptors were expressed on
the majority of tumors; however, with increasing aggressiveness
of tumor, the expression was reduced. Considering the two
groups of in¢ltrative BCC: of 17 in¢ltrative BCC, 82% expressed
P2X5 receptors but only 57% of ‘‘horrifying BCC’’ expressed
P2X5 receptors. In P2X5 receptor positive ‘‘horrifying BCC’’, the
receptor was expressed on most of the cells within it, in associa-
tion with numerous cells undergoing mitosis, unlike the other
group of in¢ltrative BCC analyzed, where P2X5 receptor expres-
sion was more polarized towards the basement membrane and
mitoses were few.
P2Y1 receptors were expressed in the stroma surrounding both
BCC and SCC, but not within the tumor cells. 2MeSADP, the
P2Y1 receptor subtype agonist, caused a reduction in A431 cell
number, although this was not statistically signi¢cant.The actions
of 2MeSADP might therefore be nonspeci¢c. It is known that for
BCC to grow, they depend on interaction with their stromal ma-
trix, and this is why it is generally thought that BCC are di⁄cult
to establish in culture. It seems that P2Y1 receptors do not have a
direct proliferative role in A431 cells.
In summary, P2X7 receptor immunostaining may be a useful
histologic tool to assess apoptosis in tumors, with the loss of ex-
pression of the marker suggesting increased tumor aggressiveness.
P2 purinergic receptor agonists alter A431 cell numbers via sev-
eral mechanisms: UTP and low concentrations of ATP cause an
increase in cell number via P2Y2 receptors; ATPgS causes a de-
crease in cell number, probably because cells are lost from the cell
cycle by being induced to di¡erentiate via activation of P2X5 re-
ceptors; BzATP and high concentrations of ATP cause a signi¢-
cant decrease in cell number via a direct e¡ect on P2X7 receptors,
which are known to be involved in mediating apoptosis.We have
demonstrated that NMSC contain purinergic receptors and that
these receptors are functional in A431 cells in vitro. This opens the
pathway for new treatment modalities in these important skin
cancers.
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